Latest News Archive

Please select Category, Year, and then Month to display items

UFS management expresses concern about number of positive COVID-19 cases

13 October 2020 | Story Lacea Loader

The Free State is currently one of the provinces in the country with the highest percentage of new tests that turn out positive for COVID-19. This also impacts on the staff and students at the University of the Free State (UFS), as the number of positive cases on the campuses has increased considerably during the past few weeks.

The UFS experienced an increase of 47% in the number of students who tested positive from Level 2 of the national lockdown to Level 1. During the past few days, an increase of 21% in positive student cases has been experienced. In the case of staff, an increase of 34% in the number who tested positive occurred from Level 2 of the national lockdown to Level 1. Over the past few days, an increase of 11% in positive cases has been experienced.

1. Adherence to national protocols and regulations

The safety, health, and well-being of staff and students remain a priority. Therefore, the university management is concerned about the rise in positive cases on the campuses and appeals to staff to adhere to the national protocols and regulations issued by the Ministers of Cooperative Governance and Traditional Affairs, Employment and Labour, Higher Education, Science and Innovation, and Health.

It is important to note that non-adherence to certain of the national protocols and regulations is a criminal offence and is punishable by a fine or imprisonment of up to six months. By not adhering to national protocols and regulations, our staff is not only putting their own health at risk, but also the health of others.

2. Behaviour observed on campus

The following behaviour has been observed among staff working on campus:
- Not adhering to social/physical distancing of 2 metres;
- Face-to-face contact without wearing masks (e.g. in boardrooms and tearooms, visiting each other in offices, etc);
- Not wearing a mask while moving on campus, as well as in buildings (except in the privacy of offices);
- Dishonesty during the screening process; and
- Non-compliance with isolation and quarantine guidelines.
Staff members are reminded that they may face disciplinary action if they do not adhere to the national COVID-19 protocols and regulations as issued by the different ministers. It is important that staff members be honest at all times during the screening process, as it has been observed that some staff members display some COVID-19-related symptoms but answer in the negative on the online screening app.

3. Reporting of positive COVID-19 cases
In terms of the directives issued by the Minister of Employment and Labour, the Minister of Health, and the Minister of Higher Education, Science and Innovation, the UFS is required to report all COVID-19 positive cases to the Department of Labour, the Department of Health, and the Department of Higher Education and Training. All COVID-19 positive cases must thus be reported directly to the Senior Director: Human Resources (vjaarsj@ufs.ac.za) and Kovsie Health (johnr@ufs.ac.za) for further handling and reporting to the relevant government departments.

Please do not come to the campuses if you are experiencing any COVID-19-related symptoms and get tested as soon as possible.

Those staff members who test positive will receive the necessary advice from their medical practitioners and they can also contact Kovsie Health for assistance.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease

2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013

The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.

In future further evaluation will be performed in other forms of hypocholesterolemia.

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.

Back

Economic and Management Sciences

Education

Health Sciences

The Humanities

Law

Natural and Agricultural Sciences

Theology and Religion

Open Distance Learning

Business School

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept